NCT00666900

Brief Summary

The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
366

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jan 2008

Geographic Reach
1 country

25 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 23, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 25, 2008

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2009

Completed
Last Updated

February 20, 2012

Status Verified

February 1, 2012

Enrollment Period

1.2 years

First QC Date

April 23, 2008

Last Update Submit

February 16, 2012

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change from baseline in the number of inflammatory lesions

    12 weeks

  • Improvement from baseline in global severity

    12 weeks

Secondary Outcomes (1)

  • Change from baseline in the number of non-inflammatory lesions

    12 weeks

Study Arms (3)

1

EXPERIMENTAL
Drug: Low Strength IDP-107

2

EXPERIMENTAL
Drug: High Strength IDP-107

3

PLACEBO COMPARATOR
Drug: Placebo Comparator

Interventions

Once a day for 12 weeks

1

Once a day for 12 weeks

2

Once a day for 12 weeks

3

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Presence of inflammatory and non-inflammatory lesions

You may not qualify if:

  • Dermatological conditions of the face that could interfere with clinical evaluations
  • Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (25)

Burke Pharmaceutical Research

Hot Springs, Arkansas, 71913, United States

Location

Dermatology Research of Arkansas, PLLC

Little Rock, Arkansas, 72205, United States

Location

RADY Children's Hospital - San Diego

San Diego, California, 92123, United States

Location

Clinical Science Institute

Santa Monica, California, 90404, United States

Location

Solano Clinical Research

Vallejo, California, 94589, United States

Location

Cherry Creek Research, Inc.

Denver, Colorado, 80209, United States

Location

FXM Research Corp.

Miami, Florida, 33175, United States

Location

Michigan Center for Skin Care Research

Clinton Township, Michigan, 48038, United States

Location

Hamzavi Dermatology

Fort Gratiot, Michigan, 48059, United States

Location

Minnesota Clinical Study Center

Fridley, Minnesota, 55432, United States

Location

Skin Specialist, PC

Omaha, Nebraska, 68144, United States

Location

Academic Dermatology Associates

Albuquerque, New Mexico, 87106, United States

Location

Dermatology Associates of Rochester

Rochester, New York, 14623, United States

Location

DermResearchCenter of New York, Inc.

Stony Brook, New York, 11790, United States

Location

University of North Carolina Hospitals and School of Medicine

Chapel Hill, North Carolina, 27599, United States

Location

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

Oregon Dermatology and Research Center

Portland, Oregon, 97210, United States

Location

Arlington Research Center, Inc.

Arlington, Texas, 76011, United States

Location

DermResearch, Inc.

Austin, Texas, 78759, United States

Location

J & S Studies, Inc.

Bryan, Texas, 77802, United States

Location

The Center for Skin Research

Houston, Texas, 77056, United States

Location

South Valley Dermatology

West Jordan, Utah, 84088, United States

Location

Virginia Clinical Research, Inc.

Norfolk, Virginia, 23507, United States

Location

Premier Clinical Research

Spokane, Washington, 99204, United States

Location

Madison Skin & Research, Inc.

Madison, Wisconsin, 53719, United States

Location

MeSH Terms

Conditions

Acne Vulgaris

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 23, 2008

First Posted

April 25, 2008

Study Start

January 1, 2008

Primary Completion

March 1, 2009

Study Completion

September 1, 2009

Last Updated

February 20, 2012

Record last verified: 2012-02

Locations